Matinas BioPharma 10K 2023 Annual report | MTNB Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abstract, agriculture, amenable, annexed, apparent, authentication, automated, Awardee, Basilea, blinded, bowel, Brexafemme, censored, CEO, Chairperson, chemotherapeutic, chest, Children, chose, CODM, colon, conjugated, Crohn, cumbersome, curve, cyber, cybersecurity, cytokine, delisted, deploy, dextran, died, directionality, Dis, disaster, docetaxel, doubt, DSS, dyspnea, East, Editor, Elion, endemic, endocytic, extrahepatic, flow, fosmanogepix, Fusarium, hematologic, hematological, Hong, Hope, hypoxia, IA, imiquimod, immaterial, IMQ, inexpensively, inflamed, infusion, innate, intracellularly, Kettering, knockdown, knocking, Kong, Lastly, lesion, malignant, manifested, manuscript, melanoma, Melinta, Memorial, metastatic, Middle, mL, multifactor, mycologic, mycological, nonpublic, ORALTO, OTC, Pacific, palliative, PCR, PCT, peak, penny, Philadelphia, phishing, pink, possession, psoriatic, radiologic, radiological, reconciling, recovery, regain, revisit, Rezzayo, Rock, skin, sodium, stem, store, sulfate, syngeneic, tangible, TNF, TPST, unresectable, Vanderbilt, worse

Removed: absorbed, accredited, accretion, acetate, achievement, adjusting, alert, amikacin, aminoglycoside, applying, ATM, background, bacterial, barrier, biologically, CF, Cidara, closed, conclusively, consecutive, deducting, emerged, encapsulation, extraordinary, fatty, feature, flexibility, fractional, gram, host, hydrophilic, immunodeficiency, immunogenicity, indemnified, Interruption, leveraged, lookout, lowering, LYPDISO, markedly, multidrug, municipal, mycobacterial, naturally, newly, NTM, optimized, outlined, perpetual, plasma, proceed, proof, regimen, resume, RNA, sixty, soy, sublicensable, suitable, survive, suspended, underscored, undesignated, vaccine, vendor, warrant, workforce

Name		State of Incorporation

Matinas BioPharma, Inc.		Delaware

Matinas BioPharma Nanotechnologies, Inc.		Delaware

Matinas BioPharma (MTNB) 10-K2023 FY Annual report

Content analysis